Genmab — December 2019

[E_L]

European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe https://www.globenewswire.com/fr/news-release/2019/12/17/1961450/0/en/European-Investment-Bank-provides-funding-of-50-million-to-BioNTech-as-part-of-the-Investment-Plan-for-Europe.html they can put it straight into the duobodies

[peter12]

Its up 6% in pre-market but lets see

[Bulder]

Det er vel ved at være på tide, at vi hører om filing af ofa i RMS?

[E_L]

they still have 2 weeks lol, swiss precision

[bibob]

E L. I have a swiss watch too. But It's a stop watch. Do you think that's a problem.

[E_L]

[E_L]

What advice can you offer to community hematologists and oncologists treating patients with transplant-ineligible NDMM?

Dr. Mateos: Always try to use the best combination first because the best combinations will benefit almost 100% of newly diagnosed myeloma patients. The maximum benefit is obtained from the first line of therapy, and some transplant-ineligible patients with NDMM will receive only one line of therapy. https://i3health.us/news/adding-daratumumab-to-vmp-for-transplant-ineligible

[E_L]

Genmab article on p 16 http://digitaledition.qwinc.com/publication/?m=53489&l=1&view=issuelistBrowser#{"issue_id":"641494","page":16}

[E_L]

Glaxo’s myeloma Dreamm turns into a nightmare https://www.evaluate.com/vantage/articles/news/trial-results/glaxos-myeloma-dreamm-turns-nightmare

[peter12]

Maybe this link is better ? http://digitaledition.qwinc.com/publication/?i=641494&ver=html5&p=16

[Solsen]

CAR-T https://finance.yahoo.com/news/gileads-second-car-t-treatment-161320198.html

[nohope]

Spændende, endda skrevet så selv jeg kunne læse det, tak.

[JKY_VH]

ser godt ud peter12:-)

[Solsen]

Kunne man håbe, at Novartis er den anonyme køber https://ml-eu.globenewswire.com/Resource/Download/3d403113-b3d8-47e1-b152-6ce5e26c3d60

[nohope]

Hvorfor vil du gerne se Novartis købe ?

[GeorgeBest]

Så de kan bruge den til at få Ofa MS hurtigere godkendt, og på markedet...

[Solsen]

Synes der er en rimelig chance for det. Timing og konkurrencesituationen samt potentialet i ofa i RRMS.

[Mcjean]

den PR var ikke så dyr før i tiden røg de til 250 mill. men i dag er det vidst meget normalt med 100-125 mill.

[Mcjean]

Solsen tror du ikke de regner med at få PR?

[Solsen]

Nej det tror jeg ikke. Så vigtig er den ikke set fra fdas side. Pts kan jo blot bruge ocrelizumab.